Tyler Menichiello’s Post

Our highly anticipated cell therapy webinar is just one week away, so secure your spot before it's too late ⏳ https://ter.li/9bwzoc Get ready to explore how allogeneic cell therapies are making waves with scalable and innovative alternatives to traditional autologous treatments. Here’s a sneak peek: 💸 Total deal value involving allogeneic cell therapies in 2023 was $981 million, but this year we’ve already surpassed that investment! 🔬 130 allogeneic trials have their end dates this year, providing a wealth of new data and insights. 🧪 Over 440 allogeneic trials are currently recruiting participants. Find out more about these promising developments. Our expert panel will dive deep into these exciting advancements. Don’t miss the chance to stay ahead of the curve and unlock the potential of cutting-edge allogeneic solutions in oncology and beyond. #CellTherapy #Allogeneic #AllogeneicTherapies #MarketInsights Hanson Wade Intelligence

Mirai Bio President and COO, Jens H. Vogel, Ph.D. captures the scalability challenges facing #celltherapies in this Cell & Gene Therapy Insights article, exploring innovative solutions like in vivo engineering to expand patient access and streamline production.

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/dR-ntd3m

Are you stressed about supply chain risks? Cell therapy manufacturers are finding ways to reduce vulnerability — and we’re here to help. Discover one company's solution in our latest case study. https://lnkd.in/efQDr2Eb #celltherapy #supplychain #riskmanagement

Leveraging living human cells to fight disease has already proven to be incredibly powerful in hematological oncology and holds huge promise, e.g. in devastating autoimmune diseases. However, autologous cell therapies are difficult to make, and 7 years after the first approvals, only about 35,000 patients have been treated with all approved products combined. We need truly breakthrough innovations to bring such therapies to all patients in need. What if.. we build targeted platforms to better engineer cells directly in vivo - skipping ex vivo cell manufacturing alltogether?! Read my short viewpoint article summarizing my thoughts. https://lnkd.in/gnZGpzvB

#FlagshipFounded Mirai Bio President & COO Jens H. Vogel, Ph.D. describes current and future innovations that aim to realize the full potential of cell and gene therapies for the benefit of patients globally in this Cell & Gene Therapy Insights article: https://lnkd.in/eWxQRu-8

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/gYyYxWyH

Most recent new literature search on 'generative + AI + drug development' : Remolding the Tumor Microenvironment by Bacteria Augments Adoptive T Cell Therapy in Advanced-Stage Solid Tumors https://lnkd.in/gXFJz9bD

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/g2M8ueiX

Gene&Cell Therapy >> Astellas stops developing autologous cell therapy for lymphoma: Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma confirmed to Endpoints News on Wednesday. The pharma giant ended a #lucidquest #genetherapy #celltherapy